Cargando…
Diagnosis and treatment of CD20 negative B cell lymphomas
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The mo...
Autores principales: | Katchi, Tasleem, Liu, Delong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297138/ https://www.ncbi.nlm.nih.gov/pubmed/28191314 http://dx.doi.org/10.1186/s40364-017-0088-5 |
Ejemplares similares
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
por: Wang, Kemeng, et al.
Publicado: (2012) -
Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012) -
Extramedullary hematopoiesis presented as cytopenia and massive paraspinal masses leading to cord compression in a patient with hereditary persistence of fetal hemoglobin
por: Katchi, Tasleem, et al.
Publicado: (2016) -
Do Certain Biomarkers Predict Adverse Outcomes in Coronavirus Disease 2019?
por: Narvel, Hiba, et al.
Publicado: (2021) -
Case report of primary CD20 negative diffuse large B-cell lymphoma
por: Devi, Kanti, et al.
Publicado: (2021)